38017-65-1

Basic information

• Product Name: H-PHE-PHE-OME HCL
• Synonyms: L-PHENYLALANYL-L-PHENYLALANINE METHYL ESTER HYDROCHLORIDE;H-PHE-PHE-OME HCL;(S)-methyl 2-((S)-2-amino-3-phenylpropanamido)-3-phenylpropanoate hydrochloride;REF DUPL: H-Phe-Phe-OMe HCl
• CAS NO: 38017-65-1
• Molecular Formula: C₁₉H₂₂N₂O₃*ClH
• Molecular Weight: 362.85
• Mol File: 38017-65-1.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: H-PHE-PHE-OME HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-PHE-PHE-OME HCL(38017-65-1)
• EPA Substance Registry System: H-PHE-PHE-OME HCL(38017-65-1)

Safety Data

• Hazardous Substances Data: 38017-65-1(Hazardous Substances Data)

Usage

Description

H-PHE-PHE-OME HCL, also known as L-Phenylalanyl-L-phenylalanine Methyl Ester Hydrochloride, is a hydrophobic dipeptide derivative that has been utilized in various applications due to its unique properties. It is characterized by its ability to form polymer nanoparticles and has shown potential in inhibiting amyloid-β fibrillation, a process associated with neurodegenerative diseases.

Uses

Used in Pharmaceutical Industry:
H-PHE-PHE-OME HCL is used as a key component in the preparation of polymer nanoparticles for the inhibition of amyloid-β fibrillation. This application is particularly relevant in the development of treatments for neurodegenerative diseases, such as Alzheimer's, where the aggregation of amyloid-β peptides plays a significant role in the pathology of the condition.
The use of H-PHE-PHE-OME HCL in the creation of polymer nanoparticles allows for the targeted delivery of the dipeptide to the affected areas, potentially reducing the overall concentration required for therapeutic effects and minimizing side effects. Additionally, the hydrophobic nature of the dipeptide may enhance its interaction with the hydrophobic regions of amyloid-β peptides, further contributing to its inhibitory effects on fibrillation.

Upstream product

• 13122-89-9 (S)-methyl 2-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropanamido)-3-phenylpropanoate 
• 133992-84-4 (S)-3-Phenyl-2-[(S)-3-phenyl-2-((Z)-4,4,4-trifluoro-3-oxo-but-1-enylamino)-propionylamino]-propionic acid methyl ester 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 51987-73-6 (S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 4192-12-5 dicyclohexylammonium N-(tert-butoxycarbonyl)-L-phenylalaninate 
• 63-91-2 L-phenylalanine 
• 133992-79-7 3-phenyl-2-[(Z)-4,4,4-trifluoro-3-oxo-1-butenylamino]propanoic acid 
• 67-56-1 methanol 
• 2577-40-4 Phe-Phe 

Downstream Products

• 143674-02-6 IBH-Phe-Phe-OMe 
• 89344-16-1 Z-Tau-Phe-Phe-OCH₃ 
• 79385-79-8 Bpoc-Asn-Phe-Phe-OMe 
• 103025-49-6 Boc-Gly-Pro-Pro-Phe-Phe-OMe 
• 77511-69-4 NPS-L-Thr(Bu^t)-L-Phe-L-Phe-OMe 
• 53558-75-1 Boc-Phe-Phe-Phe-OMe 
• 161083-57-4 <(2R)-3--2--2-methylpropanoyl>-phenylalanyl-phenylalanine methyl ester 
• 73644-69-6 L-Thr(Bu^t)-L-Phe-L-Phe-SL 
• 77511-70-7 NPS-L-Thr(Bu^t)-L-Phe-L-Phe-N₂H₃ 
• 77511-71-8 NPS-L-Thr(Bu^t)-L-Phe-L-Phe-SL 
• 143674-03-7 IBH-Phe-Phe-OH 

Relevant articles and documents

Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA

Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an attractive protein trap for drug targeting. At the present time, several drugs and molecular diagnostic tools conjugated with selective PSMA ligands are actively evaluated in different preclinical and clinical trials. In the current work, we discuss design, synthesis and a preliminary biological evaluation of PSMA-specific small-molecule carrier equipped by Doxorubicin (Dox). We have introduced an unstable azo-linker between Dox and the carrier hence the designed compound does release the active substance inside cancer cells thereby providing a relatively high Dox concentration in nuclei and a relevant cytotoxic effect. In contrast, we have also synthesized a similar conjugate with a stable amide linker and it did not release the drug at all. This compound was predominantly accumulated in cytoplasm and did not cause cell death. Preliminary in vivo evaluation has showed good efficiency for the degradable conjugate against PC3-PIP(PSMA+)-containing xenograft mine. Thus, we have demonstrated that the conjugate can be used as a template to design novel analogues with improved targeting, anticancer activity and lower rate of potential side effects. 3D molecular docking study has also been performed to elucidate the underlying mechanism of binding and to further optimization of the linker area for improving the target affinity.

Design, synthesis, and characterisation of glyoxylamide-based short peptides as self-assembled gels

The synthesis and supramolecular properties of novel glyoxylamide-based short peptides formed via the ring-opening reaction of N-acetylisatins in solution phase are described. The short peptides self-assembled into gels, which were examined for their mechanical and morphological characteristics using multiple spectroscopic and microscopy techniques. The critical gel concentration and mechanical strength of the self-assembled gels were influenced by the presence of electronegative substituents (such as fluoro, in 5b) or hydrophobic substituents (such as bromo, 5d) respectively in the short peptides. Moreover, in vitro cytotoxicity assays demonstrated that these compounds were non-toxic to mammalian cells.

Building Nanowires from Micelles: Hierarchical Self-Assembly of Alternating Amphiphilic Glycopolypeptide Brushes with Pendants of High-Mannose Glycodendron and Oligophenylalanine

Mimicking the diverse glyco-conjugate structures in nature is always the dream of scientists. Right now, hierarchical self-assembled structures of natural conjugates of peptides and sugars could not easily be achieved via linear glycopolypeptide with mono